Suvoda Launches eCOA-Specific Language and Design Toolkit
Functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience.
Suvoda announced that as part of its single platform rollout, its eCOA solution is moving to the second phase of the Early Adopter program. This solution, designed to work with Suvoda IRT and eConsent, focuses on addressing eCOA challeneges such as gaps in overall delivery and execution quality, time consuming translations and localization processes, and logistics related to device management.
Read more about the solution
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
